Ardelyx Inc. ARDX, +5.02% stock is up 5.2% in premarket trades on Thursday after the Waltham, Mass., biopharmaceutical company said the U.S. Food and Drug Administration granted an appeal for its Xphozah medicine. Ardelyx said it plans to resubmit its New Drug Application (NDA) for Xphozah in the first half of 2023. Xphozah could be the first phosphate absorption inhibitor for kidney patients on dialysis treatment. The FDA granted an appeal to a Complete Response Letter for a NDA for Xphozah.
This article was originally published by Marketwatch.com. Read the original article here.
